Research
Hormonal
Semaglutide significantly improves glycemic control (HbA1c and fasting blood glucose) and systolic blood pressure in overweight or obese adults, with or without type 2 diabetes.
Semaglutide not only helps with weight loss but also significantly improves blood sugar control (HbA1c and fasting glucose) and lowers systolic blood pressure in overweight or obese individuals, offering potential cardiovascular benefits.
GoodSupportsHIGH confidence
Meta-analysis showed that compared with the control group, the semaglutide group was reduced more significantly in... glycosylated hemoglobin (RR = −0.66, 95% CI [−1.07, −0.25], P = 0.002), fasting blood glucose values (RR = −4.81, 95% CI [−7.03, −2.60], P < 0.001), and systolic blood pressure (RR = −3.37, 95% CI [−5.32, −1.42], P < 0.001)
Why this rating
Based on meta-analysis of RCTs, though heterogeneity was high for some lipid markers.
Source
Effectiveness and safety of semaglutide in overweight/obese adults with or without type 2 diabetes: A systematic review and meta-analysis
Yang Liu et al. · Journal of Research in Medical Sciences · 2024
DOI 10.4103/jrms.jrms_693_23
Meta-analysis · 15 studiesCited 3×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Semaglutide (GLP-1 receptor agonist) significantly reduces body weight, BMI, and waist circumference in overweight or obese adults, with or without type 2 diabetes, compared to placebo or other glucose-lowering medications.Good
- Semaglutide increases the proportion of patients achieving significant weight loss thresholds (>5%, >10%, >15%, and >20%) compared to control groups.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →